Authors' recommendations: Peripheral T-cell lymphoma is a rare form of lymphoma, a cancer affecting a type of white blood cell called a lymphocyte. At the beginning, the symptoms of lymphoma can be very varied and difficult to diagnose, but as the lymph nodes get bigger, a painless swelling in the neck, armpit or groin is sometimes noticed. The condition generally affects people aged over 60 years of age and it is slightly, more common in men than in women. By the time they are diagnosed, the lymphoma has often spread widely around the body. The main treatment is chemotherapy, but not all patients are well enough to manage this and the disease often returns after treatment. Masitinib is a new drug for the treatment of peripheral T-cell lymphoma that is taken as a tablet twice a day. It is being studied at the moment to see how well it works and whether it is safe to use. If it is licensed for use in the UK, it would be a new treatment option that could improve the life expectancy of patients whose lymphoma has returned after their first treatment has stopped working.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/masitinib-for-relapsed-or-refractory-peripheral-t-cell-lymphoma/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)